Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 19/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 14/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593099 | 0.82 | CSNK1D (0.44) | CSNK1DCSNK1E | |
| SCHEMBL3588335 | 0.75 | BTK (0.48) | CSNK1DCSNK1ECDK4 | |
| SCHEMBL3595696 | 0.73 | CDK1 (0.59) | — | |
| SCHEMBL3586487 | 0.72 | ABL1 (0.39) | CSNK1DCSNK1ECDK4 | |
| SCHEMBL3589147 | 0.72 | CSNK1D (0.46) | CSNK1DCSNK1ECDK4CCND1CDK6 | |
| SCHEMBL3585124 | 0.71 | CDK1 (0.48) | CSNK1DCSNK1E | |
| SCHEMBL3601333 | 0.70 | AURKA (0.39) | CSNK1DCSNK1E | |
| SCHEMBL3590041 | 0.66 | CSNK1D (0.41) | CSNK1DCSNK1ECDK13CDK12 | |
| SCHEMBL1590587 | 0.66 | CSNK1D (0.51) | CSNK1DCSNK1ECDK13CDK12 | |
| SCHEMBL3591938 | 0.65 | CSNK1D (0.47) | CSNK1DCSNK1ECDK4CCND1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | claimed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | claimed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | CSNK1D 1542/4885CSNK1E 1264/4885CDK4 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.